Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENO1 | P06733 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11776821 | 0.86 | LMNA (0.40) | ENO1SMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL28881823 | 0.81 | MAPT (0.54) | ENO1SMN1; SMN2LMNAL3MBTL1POLB | |
| SCHEMBL11775144 | 0.80 | ENO1 (0.34) | ENO1SMN1; SMN2LMNAMAPTALDH1A1 | |
| SCHEMBL23107969 | 0.78 | POLB (0.35) | SMN1; SMN2L3MBTL1POLBALDH1A1MAPK1 | |
| SCHEMBL1978459 | 0.78 | MAPT (0.47) | SMN1; SMN2LMNAL3MBTL1POLBMAPT | |
| SCHEMBL17450553 | 0.77 | POLB (0.33) | SMN1; SMN2LMNAL3MBTL1POLBMAPT | |
| SCHEMBL28286528 | 0.76 | ENO1 (0.40) | ENO1SMN1; SMN2LMNAL3MBTL1POLB | |
| SCHEMBL12208276 | 0.74 | MAPK1 (0.39) | ENO1SMN1; SMN2LMNAL3MBTL1POLB | |
| SCHEMBL25106761 | 0.73 | NOTUM (0.34) | SMN1; SMN2L3MBTL1POLBMAPTALDH1A1 | |
| SCHEMBL4962139 | 0.73 | ENO1 (0.40) | ENO1SMN1; SMN2LMNAMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116803989-A | Preparation process of 1-N-methyl-2-nitro-5-hydroxymethyl imidazole | 深圳艾欣达伟医药科技有限公司 | 2023-09-26 | — | — | CN | claimed |
| US-12115226-B2 | Linker containing arylnitro, antibody-drug conjugate containing linker and use of linker | ACADEMY OF MILITARY MEDICAL SCIENCES (CN) | 2024-10-15 | — | — | US | disclosed |
| CN-117756848-A | TH-302 derivative and preparation method thereof | 常州大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-116803989-A | Preparation process of 1-N-methyl-2-nitro-5-hydroxymethyl imidazole | 深圳艾欣达伟医药科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| US-20210205464-A1 | Linker Containing Arylnitro, Antibody-Drug Conjugate Containing Linker and Use of Linker | ZHEJIANG YANGSHENGTANG INSTITUTE OF NATURAL MEDICATION CO., LTD. (CN) | 2021-07-08 | — | — | US | disclosed |
| EP-3845251-A1 | LINKER CONTAINING ARYLNITRO, ANTIBODY-DRUG CONJUGATE CONTAINING LINKER AND USE OF LINKER | Academy of Military Medical Sciences (CN) | 2021-07-07 | — | — | EP | disclosed |
| US-10654876-B2 | TH-302 solid forms and methods related thereto | MOLECULAR TEMPLATES, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| WO-2020043129-A1 | LINKER CONTAINING ARYLNITRO, ANTIBODY-DRUG CONJUGATE CONTAINING LINKER AND USE OF LINKER | 中国人民解放军军事科学院军事医学研究院 | 2020-03-05 | — | — | WO | disclosed |
| US-20190127404-A1 | TH-302 SOLID FORMS AND METHODS RELATED THERETO | MOLECULAR TEMPLATES, INC. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20170210769-A1 | TH-302 SOLID FORMS AND METHODS RELATED THERETO | THRESHOLD PHARMACEUTICALS, INC. (US) | 2017-07-27 | — | — | US | disclosed |
| US-8003625-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003625-B2 | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-2336141-A2 | Phosphoramidate alkylator prodrugs | Threshold Pharmaceuticals, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| EP-2336141-A2 | Phosphoramidate alkylator prodrugs | Threshold Pharmaceuticals, Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20100137254-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | IMMUNOGENESIS, INC. | 2010-06-03 | — | — | US | disclosed |
| US-20100137254-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | IMMUNOGENESIS, INC. | 2010-06-03 | — | — | US | disclosed |
| CN-101501054-A | Phosphoramidate alkylator prodrugs | THRESHOLD PHARMACEUTICALS INC (US) | 2009-08-05 | — | — | CN | disclosed |
| EP-1896040-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | Threshold Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007002931-A2 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2000064864-A9 | N-PROTECTED AMINES AND THEIR USE AS PRODRUGS | CANCER RES CAMPAIGN TECH (GB) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205464-A1 | Linker Containing Arylnitro, Antibody-Drug Conjugate Containing Linker and Use of Linker | BCR, FCGRT, ERBB2 | ENO1 360/4885SMN1; SMN2 1146/4885LMNA 1264/4885 |
| US-20100137254-A1 | PHOSPHORAMIDATE ALKYLATOR PRODRUGS | TYMP, PAICS, PNP | ENO1 1951/4885SMN1; SMN2 1598/4885LMNA 3316/4885 |
| US-10654876-B2 | TH-302 solid forms and methods related thereto | THPO, TBXAS1, TMSB4X | ENO1 1702/4885SMN1; SMN2 761/4885LMNA 2551/4885 |
| US-12115226-B2 | Linker containing arylnitro, antibody-drug conjugate containing linker and use of linker | BCR, FCGR2A, FCGRT | ENO1 496/4885SMN1; SMN2 1159/4885LMNA 1130/4885 |
| US-20190127404-A1 | TH-302 SOLID FORMS AND METHODS RELATED THERETO | THPO, TBXAS1, TMSB4X | ENO1 1702/4885SMN1; SMN2 761/4885LMNA 2551/4885 |
| US-20170210769-A1 | TH-302 SOLID FORMS AND METHODS RELATED THERETO | THPO, TBXAS1, TMSB4X | ENO1 1702/4885SMN1; SMN2 761/4885LMNA 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.